Contribute Try STAT+ Today

In a notable development for preventing HIV, an interim analysis found that an every-other-month injectable treatment was 89% more effective in preventing infection among women than the Truvada pill, which must be taken daily and is the current standard of care.

The analysis was disclosed after an independent data safety monitoring board recommended early unblinding — or disclosing details — of a clinical trial testing the injectable treatment, which is called cabotegravir and was developed by ViiV Healthcare. The primary goal of the trial was to demonstrate the injectable medication is superior to the pill, which is sold by Gilead Sciences (GILD).

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.